Showing 2121-2130 of 2837 results for "".
- Juvéderm Vollure XC FDA Approved for Correction of Facial Wrinkles and Foldshttps://modernaesthetics.com/news/juvderm-vollure-xc-fda-approved-for-correction-of-facial-wrinkles-and-folds/2472255/The FDA has approved Allergan plc's Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US pivotal clinical trial, a majority (59 percent) of subjects saw improvement in moderate to severe na
- ASAPS: Americans Spent Big on Cosmetic Surgery in 2016https://modernaesthetics.com/news/asaps-americans-spent-big-on-cosmetic-surgery-in-2016/2472257/15 + B That’s the amount of money that Americans doled out for cosmetic surgery in 2016, according to newly released statistics from the American Society for Aesthetic Plastic Surgery (ASAPS). That’s 1.5 B more then they spe
- Survey: Many Bothered By Double Chins, Take Steps To Cover Uphttps://modernaesthetics.com/news/survey-many-bothered-by-double-chins-take-steps-to-cover-up/2472259/Close to 50 percent of individuals are bothered by the appearance of the area under their chin, and many alter their behavior as a result, according to a new survey commissioned by Allergan plc.<
- Zeltiq Showcases CoolAdvantage Petite Applicator at AAD Annual Meetinghttps://modernaesthetics.com/news/zeltiq-showcases-cooladvantage-petite-applicator-at-aad-annual-meeting/2472261/ZELTIQ® Aesthetics is showcasing the CoolAdvantage Petite™ applicator at the American Academy of Dermatology Annual Meeting (AAD) in Orlando. The CoolAdvantage technology is the only non-invasive fat removal technology cleared by the
- Galderma, Colorescience to Collaborate on Innovative Skincarehttps://modernaesthetics.com/news/galderma-colorescience-to-collaborate-on-innovative-skincare/2472266/Galderma will collaborate with Colorescience to expand skincare solutions to individuals who seek innovative daily skincare products that can be used in conjunction with traditional facial injectable aesthetic treatments, the companies have announced. Galderma and
- ASPS 2016 Stats: Cosmetic Surgery On The Risehttps://modernaesthetics.com/news/asps-2016-stats-cosmetic-surgery-on-the-rise/2472267/Fat is still phat – at least in some places like the breasts, butt and face, according to the annual statistics from the American Society of Plastic Surgeons (ASPS). Specifically, minimally invasive cosmetic fat injections incre
- Cynosure to Be Acquired by Hologichttps://modernaesthetics.com/news/cynosure-to-be-acquired-by-hologic/2472278/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billion
- Aesthetics Wire Exclusive: AAFPRS Survey Shows Combination Facial Plastic Surgery Treatment Requests Are Soaringhttps://modernaesthetics.com/news/aesthetics-wire-exclusivecombination-facial-plastic-surgery-treatment-requests-soaring/2472289/Combination therapies reign supreme, according to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) 2016 statistics. In 2016, 66 percent of facial plastic surgeons reported performing combined non-surgical procedures in the same
- AAD Selects ContextMedia:Health as Patient Education Affinity Partnerhttps://modernaesthetics.com/news/aad-selects-contextmediahealth-as-patient-education-affinity-partner/2472318/ContextMedia:Health is now an Affinity Partner with the American Academy of Dermatology (AAD). The partnership offers ContextMedia:Health's suite of digital technology to the AAD's U.S. members at no cost. The agreement also bring
- Syneron Candela's Profound SubQ FDA Approved to Improve Cellulitehttps://modernaesthetics.com/news/syneron-candelas-profound-subq-fda-approved-to-improve-cellulite/2472321/Syneron Candela received FDA 510(k) clearance for Profound when using the SubQ handpiece and cartridge to improve the appearance of cellulite in patients with Fitzpatrick skin types I-III, as supported by long term data (6 months). A recent multi-center clinical study of Profound sh